Gubra A/S

GUBRA · Nasdaq Copenhagen · Healthcare

298.80DKK +0.7%last day

Price as of 2 October 2026

The price over the past year, with dividends: −24.9%

Performance

1 month

−19.9%

1 year

−24.9%

3 years, per year

+46.5%

5 years, per year

–

Largest fall, 3 years

−54.9%

Below the peak now

−53.6%

Volatility, 1 year

53.6%

Return with dividends reinvested.

Key figures

P/E

negative earnings

P/B

4.6

Dividend yield

0.0%

Return on equity

−17.4%

Net margin

−67.2%

Market value

739 m USD

Quality, value and trend

Where Gubra stands against every Nordic stock today. 100 is best.

Quality26

Profitability and a sound balance sheet over time. Better than 26% of Nordic stocks.

Value8

The price measured against earnings, assets and cash flow. Better than 8% of Nordic stocks.

Trend23

The price development over the past year. Better than 23% of Nordic stocks.

Combined4

Quality, value and trend together. Better than 4% of Nordic stocks.

About Gubra

Gubra A/S is a company in healthcare, listed on Nasdaq Copenhagen. The share trades in DKK. It has around 330 employees.

Gubra A/S, a disease-agnostic techbio company, focuses on the peptide-based drug discovery and preclinical contract research services in Europe, North America, and internationally. It operates through three segments: Preclinical Contract Research (CRO), Biotech, and Gubra Green. The company offers preclinical contract research and development services within metabolic and fibrotic diseases for the pharmaceutical and biotechnology industry; and various services in vivo pharmacology, biomarker assays, bioinformatics, next gen sequencing, bioinformatics, and 2D and 3D histology with artificial intelligence pathology.

See the full analysis in InvestWiser.

The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.

See the full analysis